Urinary microRNA in Diabetic Kidney Disease: A Literature Review

Author:

Lee Chin-Chan1,Chen Chia-Chun23ORCID,Hsu Cheng-Kai1ORCID,Chen Yih-Ting1,Chen Chun-Yu1ORCID,Yang Kai-Jie1,Hung Ming-Jui4,Wu I-Wen15ORCID

Affiliation:

1. Department of Nephrology, Chang Gung Memorial Hospital, Keelung 204, Taiwan

2. Molecular Medicine Research Center, Chang Gung University, Taoyuan 333, Taiwan

3. Department of Laboratory Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 333, Taiwan

4. Department of Cardiology, Chang Gung Memorial Hospital, Keelung 204, Taiwan

5. College of Medicine, Chang Gung University, Taoyuan 333, Taiwan

Abstract

Diabetic kidney disease is the most common primary disease of end-stage kidney disease globally; however, a sensitive and accurate biomarker to predict this disease remains awaited. microRNAs are endogenous single-stranded noncoding RNAs that have intervened in different post-transcriptional regulations of various cellular biological functions. Previous literatures have reported its potential role in the pathophysiology of diabetic kidney disease, including regulation of Transforming Growth Factor-β1-mediated fibrosis, extracellular matrix and cell adhesion proteins, cellular hypertrophy, growth factor, cytokine production, and redox system activation. Urinary microRNAs have emerged as a novel, non-invasive liquid biopsy for disease diagnosis. In this review, we describe the available experimental and clinical evidence of urinary microRNA in the context of diabetic kidney disease and discuss the future application of microRNA in routine practice.

Funder

Chang Gung Memorial Hospital

Publisher

MDPI AG

Subject

General Medicine

Reference89 articles.

1. WHO (2022, October 30). Improving Health Outcomes of People with Diabetes Mellitus: Target Setting to Reduce the Global Burden of Diabetes Mellitus by 2030. Available online: https://www.who.int/publications/m/item/improving-health-outcomes-of-people-with-diabetes-mellitus.

2. Federation, I.D. (2021, September 13). IDF Diabetes Atlas. Ninth edition 2019. Available online: www.diabetesatlas.org.

3. Incretin drugs in diabetic kidney disease: Biological mechanisms and clinical evidence;Alicic;Nat. Rev. Nephrol.,2021

4. System, U.S.R.D. (2020). 2020 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States.

5. Chronic Kidney Disease;Webster;Lancet,2017

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3